LFST

LifeStance Health Group, Inc. (LFST) | Rumor.io

LifeStance Health Group

LFST

Attention (50-day avg)0%

Attention rank (50-day avg)#1,628

Bullish sentiment (50-day avg)96%

Price to earnings ratio91.1

Market capitalization4.5B

Earnings per share0.13

Dividend yield (TTM)—

Revenue (annual)1.4B

Net income (annual)9.7M

Social

What share of all stock conversation is about LFST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 10

$LFST (LifeStance Health Group, Inc.) has seen a significant increase in stock price, reaching a fresh 52-week high of $12.42, with a gain of +12.4% on the day.
The company has reported strong quarterly results, including 26% revenue growth, a swing to net profitability, and an upgraded full-year outlook, leading to a strong quarterly report.
LifeStance Health has doubled its adjusted profit, with the stock price reaching $12.18, and has been added as a new long idea by Hedgeye.

Generated by AI

Sentiment

Of the messages about LFST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +8.33	95.81% +26.39
Bearish	—	0% 0	0% -8.33	4.19% -26.39

Bullish· Aug 13

$LFST has the potential to reach $32-$36, with a possible price target of $36 as estimated by reputable firms like JPMorgan, UBS, and Morgan Stanley.
The company is expected to show strong growth in EPS, with a 24.60% yearly growth rate over the next 5 years, and a 53.15% average revenue growth rate over the same period.
$LFST has already shown a strong bounce, with a 21.4% stock gain, and is expected to continue its upward trend, with some analysts predicting a price increase to $20+ or more.

Bearish· Feb 1

$LFST has a history of rapid executive turnover, with 3 CFOs in 3 years, a potential red flag for financial stress.
$LFST insiders and private equity backers have sold ~$243 million in stock since the 2021 IPO, with company management selling ~$18 million, indicating potential lack of confidence in the company's future.
$LFST has been accused of overpromising on compensation to clinicians, leading to retention issues, lawsuits, and a culture of indebtedness, which may negatively impact the company's ability to attract and retain top talent.

Generated by AI

Topics

Of the messages about LFST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	75%	39.48%
Announcements	—	0%	20%	11.59%
Earnings	—	0%	0%	20.17%
Analysts	—	0%	5%	20.17%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	8.58%

Analysts· Jul 6

Morgan Stanley and JPMorgan Chase initiate coverage on LifeStance Health Group with Overweight ratings and a price target of $36.
UBS and Goldman Sachs initiate coverage on LifeStance Health Group with Buy and Neutral ratings, respectively, with price targets of $34 and $25.
William Blair initiates coverage on LifeStance Health Group with an Outperform rating and a price target not specified.

Announcements· Mar 8

LifeStance Health Group, Inc. ($LFST) reported Q4-2022 earnings with EPS increasing by 78% to -$0.13.
Revenue decreased by 73% to $229.36M, surpassing the estimated $216.61M.
LifeStance Health Group's FY EPS of -$0.61 missed the estimated -$0.60, while revenue of $859.54M exceeded the estimated $846.80M.

Controversies· Aug 26

A class action lawsuit has been filed on LifeStance Health Group investors, with a law firm encouraging investors to contact them before October.
The lawsuit is likely related to potential issues with LifeStance Health Group's business practices or financial performance.
Investors are being advised to seek legal action, suggesting potential controversy or wrongdoing within the company.

Generated by AI

Community

Of the messages about LFST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	15.22%	39.8%
Newcomers	0%	50%	84.78%	60.2%

Regulars· Feb 28

The company's short position is highlighted due to concerns over disclosures, clinician turnover, and health plan networks, but the author is now long on the stock.
The high demand for the company's services, coupled with out-of-pocket costs favoring the company, and a new CEO likely improving performance, are cited as reasons for the author's shift from being short to long on the stock.
The company's settlement with investors over IPO documentation issues is still relevant, with investors able to seek payment from the $70M settlement.

Newcomers· Aug 10

$LFST is a top gainer in the market, with a 12% increase today and one of the highest gains among stocks.
Newcomer analysts are highlighting LifeStance Health's strong quarterly report, with 26% revenue growth, a swing to net profitability, and an upgraded full-year outlook.
The stock has reached a fresh 52-week high, with some analysts pointing to a profitability inflection around Q2 '25 and strong estimates revisions, while others have identified it as an undiscovered breakout with 584 watchers.

Generated by AI

News

What’s Going On With LifeStance Health Group (LFST)?

1d agoYahoo Finance

LifeStance Health CTO Sells 42,067 Shares for $541,402 | The Motley Fool

Despite the sale, the insider still holds 205,000 shares worth $2.6 million.

7d agoThe Motley Fool

LifeStance Health Group (LFST): Buy, Sell, or Hold Post Q2 Earnings?

The past six months have been a windfall for LifeStance Health Group’s shareholders. The company’s stock price has jumped 92.6%, hitting $12.58 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

8d agoYahoo Finance

3 Low-Volatility Stocks with Open Questions

Detailed price information for Choice Hotels International (CHH-N) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

LifeStance Health Group (NASDAQ:LFST): Strongest Q2 Results from the Outpatient & Specialty Care Group

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at LifeStance Health Group (NASDAQ:LFST) and its peers.

13d agoYahoo Finance

LifeStance Health at Morgan Stanley conference: growth, margins in focus

14d agoInvesting.com

Also Discussed

Investors talking about LFST also mention

#	Name	Attention
1	SGI Enhanced Market Leaders ETFLDRX	0%0
2	JPMorgan Healthcare Leaders ETFJDOC	0%0
3	Invesco S&P SmallCap Consumer Staples ETFPSCC	0%0
4	VinFast Auto Ltd. WarrantVFSWW	0%0
5	Solid Power, Inc. WarrantSLDPW	0%0
6	Embecta Corp.EMBC	0%new
7	Direxion Daily MSFT Bull 2X SharesMSFU	0.37%new
8	HF Foods Group Inc.HFFG	0%0
9	Hennessy Advisors, Inc.HNNA	0%new
10	Sprott Copper Miners ETFCOPP	0%+0

LifeStance Health Group, Inc.

Healthcare
Medical Care Facilities

LifeStance Health Group, Inc. is a U.S. behavioral health services company that provides outpatient mental healthcare for children, adolescents, adults, and older patients. LifeStance offers psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. Its care model combines in-person visits at a broad network of centers with virtual appointments through its digital platform, giving patients access to coordinated mental health support across multiple settings. The company serves a wide range of common mental health needs through evidence-based, medically guided services delivered by licensed clinicians. LifeStance Health Group, Inc. focuses on outpatient care and operates as a single mental health services segment, making it a specialized provider within the healthcare market.

Website

Location

4800 North Scottsdale Road

Scottsdale, AZ, 85251

United States

Social

What share of all stock conversation is about LFST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 10

$LFST (LifeStance Health Group, Inc.) has seen a significant increase in stock price, reaching a fresh 52-week high of $12.42, with a gain of +12.4% on the day.
The company has reported strong quarterly results, including 26% revenue growth, a swing to net profitability, and an upgraded full-year outlook, leading to a strong quarterly report.
LifeStance Health has doubled its adjusted profit, with the stock price reaching $12.18, and has been added as a new long idea by Hedgeye.

Generated by AI

Sentiment

Of the messages about LFST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +8.33	95.81% +26.39
Bearish	—	0% 0	0% -8.33	4.19% -26.39

Bullish· Aug 13

$LFST has the potential to reach $32-$36, with a possible price target of $36 as estimated by reputable firms like JPMorgan, UBS, and Morgan Stanley.
The company is expected to show strong growth in EPS, with a 24.60% yearly growth rate over the next 5 years, and a 53.15% average revenue growth rate over the same period.
$LFST has already shown a strong bounce, with a 21.4% stock gain, and is expected to continue its upward trend, with some analysts predicting a price increase to $20+ or more.

Bearish· Feb 1

$LFST has a history of rapid executive turnover, with 3 CFOs in 3 years, a potential red flag for financial stress.
$LFST insiders and private equity backers have sold ~$243 million in stock since the 2021 IPO, with company management selling ~$18 million, indicating potential lack of confidence in the company's future.
$LFST has been accused of overpromising on compensation to clinicians, leading to retention issues, lawsuits, and a culture of indebtedness, which may negatively impact the company's ability to attract and retain top talent.

Generated by AI

Topics

Of the messages about LFST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	75%	39.48%
Announcements	—	0%	20%	11.59%
Earnings	—	0%	0%	20.17%
Analysts	—	0%	5%	20.17%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	8.58%

Analysts· Jul 6

Morgan Stanley and JPMorgan Chase initiate coverage on LifeStance Health Group with Overweight ratings and a price target of $36.
UBS and Goldman Sachs initiate coverage on LifeStance Health Group with Buy and Neutral ratings, respectively, with price targets of $34 and $25.
William Blair initiates coverage on LifeStance Health Group with an Outperform rating and a price target not specified.

Announcements· Mar 8

LifeStance Health Group, Inc. ($LFST) reported Q4-2022 earnings with EPS increasing by 78% to -$0.13.
Revenue decreased by 73% to $229.36M, surpassing the estimated $216.61M.
LifeStance Health Group's FY EPS of -$0.61 missed the estimated -$0.60, while revenue of $859.54M exceeded the estimated $846.80M.

Controversies· Aug 26

A class action lawsuit has been filed on LifeStance Health Group investors, with a law firm encouraging investors to contact them before October.
The lawsuit is likely related to potential issues with LifeStance Health Group's business practices or financial performance.
Investors are being advised to seek legal action, suggesting potential controversy or wrongdoing within the company.

Generated by AI

Community

Of the messages about LFST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	15.22%	39.8%
Newcomers	0%	50%	84.78%	60.2%

Regulars· Feb 28

The company's short position is highlighted due to concerns over disclosures, clinician turnover, and health plan networks, but the author is now long on the stock.
The high demand for the company's services, coupled with out-of-pocket costs favoring the company, and a new CEO likely improving performance, are cited as reasons for the author's shift from being short to long on the stock.
The company's settlement with investors over IPO documentation issues is still relevant, with investors able to seek payment from the $70M settlement.

Newcomers· Aug 10

$LFST is a top gainer in the market, with a 12% increase today and one of the highest gains among stocks.
Newcomer analysts are highlighting LifeStance Health's strong quarterly report, with 26% revenue growth, a swing to net profitability, and an upgraded full-year outlook.
The stock has reached a fresh 52-week high, with some analysts pointing to a profitability inflection around Q2 '25 and strong estimates revisions, while others have identified it as an undiscovered breakout with 584 watchers.

Generated by AI

LifeStance Health Group

Social

Aug 10

Bullish· Aug 13

Bearish· Feb 1

Analysts· Jul 6

Announcements· Mar 8

Controversies· Aug 26

Regulars· Feb 28

Newcomers· Aug 10

What’s Going On With LifeStance Health Group (LFST)?

LifeStance Health CTO Sells 42,067 Shares for $541,402 | The Motley Fool

LifeStance Health Group (LFST): Buy, Sell, or Hold Post Q2 Earnings?

3 Low-Volatility Stocks with Open Questions

LifeStance Health Group (NASDAQ:LFST): Strongest Q2 Results from the Outpatient & Specialty Care Group

LifeStance Health at Morgan Stanley conference: growth, margins in focus

Also Discussed

LifeStance Health Group, Inc.

Company Information

Location

What’s Going On With LifeStance Health Group (LFST)?

LifeStance Health CTO Sells 42,067 Shares for $541,402 | The Motley Fool

LifeStance Health Group (LFST): Buy, Sell, or Hold Post Q2 Earnings?

3 Low-Volatility Stocks with Open Questions

LifeStance Health Group (NASDAQ:LFST): Strongest Q2 Results from the Outpatient & Specialty Care Group

LifeStance Health at Morgan Stanley conference: growth, margins in focus

Also Discussed

Social

Aug 10

Bullish· Aug 13

Bearish· Feb 1

Analysts· Jul 6

Announcements· Mar 8

Controversies· Aug 26

Regulars· Feb 28

Newcomers· Aug 10